Paul Cook, MD
Infectious Disease · Greenville, NCNPI 1760482970
Payments from drug & device makers
Across 349 payments — averaging $8346.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.5M
- Janssen Research & Development, LLC$544K
- Gilead$382K
- AbbVie$200K
- Merck$117K
- Viiv Healthcare Company$71K
- plus $89K from 17 others
Across 12 payments — averaging $142.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1K
- Eli Lilly$378
What the payments were for
- Consulting fees$6555%
- Travel & lodging$11,20183%
- Food & beverage$1,46611%
- Education$811%
- Gifts$881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 11 | $1,509,632 |
| Janssen Research & Development, LLC | 33 | $544,184 |
| Gilead | 138 | $382,266 |
| AbbVie(2 entities) | 28 | $199,891 |
| Merck | 20 | $116,949 |
| Viiv Healthcare Company | 73 | $71,038 |
| Pfizer | 19 | $40,023 |
| Roche TCRC, Inc. | 4 | $33,141 |
| AstraZeneca | 2 | $14,950 |
| Intervascular | 1 | $655 |
| Johnson & Johnson | 7 | $106 |
| Janssen Products, LP | 1 | $30 |
| Insmed, Inc. | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Theratechnologies Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Shionogi Inc | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $11 |
| Janssen Scientific Affairs, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InterGard$655
How this compares
$2,913,054 in reported general payments places this provider in the 95th percentile of 250 infectious disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 210 | $818,482 |
| TivicayDolutegravir Sodium | 187 | $408,171 |
| PrezcobixDarunavir/Cobicistat | 156 | $375,305 |
| DovatoDolutegravir Sodium/Lamivudine | 93 | $248,107 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 47 | $234,937 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 46 | $150,316 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $96,473 |
| OzempicSemaglutide | 15 | $13,724 |
| JanuviaSitagliptin Phosphate | 13 | $12,025 |
| BelsomraSuvorexant | 12 | $4,766 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 18 | $3,871 |
| Lamivudine-ZidovudineLamivudine/Zidovudine | 20 | $2,122 |
| AbacavirAbacavir Sulfate | 12 | $1,604 |
| ValacyclovirValacyclovir Hcl | 18 | $947 |
| Ethambutol Hcl | 13 | $932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $382,266 | $818,482210 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Triumeq | $71,038 | $752,750305 claims |
| Johnson & JohnsonPrezcobix | $106 | $375,305156 claims |
| Janssen Products, LPSymtuza | $30 | $234,93747 claims |
| MerckJanuvia, Belsomra | $116,949 | $16,79225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 infectious disease providers in North Carolina.
Other infectious disease in Greenville
- Thomas GallaherGreenville$155K
- Rabindra GhimireGreenville$15K
- Alexandra StangGreenville$12K
- John SandersWinston Salem$5.2M
- Cristina GasparettoDurham$3.2M
- Susanna NaggieDurham$2.7M
- John SandersWilmington$2.4M
- Mitchell HorwitzDurham$2M
- Cornelius van DamGreensboro$2M
- Frederick CruickshankHuntersville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.